Global drugmakers call for improvement of Russian pharma legislation

Leading global pharmaceutical manufacturers operating in the Russian market have expressed their concerns regarding current Russian legislation in the field of pharmaceuticals, which prevents their further investments in the local market, according to Vladimir Shipkov, executive director of the Association of International Pharmaceutical Manufacturers in Russia, reports The Pharma Letter’s local correspondent.

Mr Shipkov comments: “We do not understand the rules of the game on the Russian pharmaceutical market. This also applies to long-term contracts. Further investments depend on the regulatory policy of the federal government.”

At the same time, according to Viktor Dmitriev, chief executive of the Association of Russian Pharmaceutical Manufacturers, the Russian pharmaceutical market still remains attractive for foreign drugmakers, although much will depend on future state policy in the local pharmaceutical market.